Trial Profile
RESOLUTE Asia: Evaluation of the Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in a Patient Population With Long Lesion(s) and/or Dual Vessels in Asia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Zotarolimus (Primary)
- Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Ischaemic heart disorders; Myocardial ischaemia; Unstable angina pectoris
- Focus Therapeutic Use
- Acronyms RESOLUTE Asia
- Sponsors Medtronic
- 09 Jun 2016 Status changed from active, no longer recruiting to completed.
- 02 May 2012 Actual patient number added 312 according to ClinicalTrials.gov.
- 02 May 2012 Planned End Date changed from 1 Aug 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.